Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2006-06-27
2006-06-27
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S279000, C514S249000, C514S264100
Reexamination Certificate
active
07067658
ABSTRACT:
The present invention provides compounds of Formula I:wherein the variables A, B, Ar, R1, R2, and R3are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.
REFERENCES:
patent: 5236901 (1993-08-01), Burks et al.
patent: WO 97/44038 (1997-11-01), None
patent: WO 98/08846 (1998-03-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 01/62758 (2001-08-01), None
patent: WO 02/19975 (2002-03-01), None
David A. Gutman, Michael J. Owens, Kelly H. Skelton, K. V. Thrivikraman, and Charles B. Nemeroff, J. Pharmacol. Exp. Ther., Feb. 2003; 304: 874-880.
SC Heinrichs, EB De Souza, G Schulteis, JL , Neuropsychopharmacology, 2002, 27:194-202.
Kamal E. Habib, Katherine P. Weld, Kenner C. Rice, Judy Pushkas, Maribeth Champoux, Samuel Listwaa, Elizabeth L. Webster, Arthur J. Atkinson, Jay Schulkin, Carlo Contoregg, George P. Chrousos, PNAS, May 23, 2000, vol. 97, No. 11, 6079-6084.
Wolff, Manfred E. “Burger's Mdeicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Taylor, Edward C.; Thompson, Malcolm J.; Perlman, Katherine; Mengel, Rudolf; Pfleiderer, Wolfgang, Journal of Organic Chemistry, 36(26), 4012-25 (English) 1971.
E. Anthony Evans in Principles of Radiopharmacology, Colombetti, L.G. editor, CRC Press, 1979, pp. 11-13, and 24.
Arborelius, L., et al., “The role of corticotrophin-releasing factor in depression and anxiety disorders,”J. of Endocrinology, 1999, 160, 1-12.
Arvanitis, A.G., et al., “Imidazo[4,5-c]pyridines as corticotrophin releasing factor receptor ligands,”Bioorg. &Med. Chem. Lett., 2003, 13, 129-31.
Boissier, J.R., et al., “A new method for rapid screening of minor tranquillizers in mice,”Eur. J. Pharmacol., 1968, 4, 145-151.
Boulton, A.J. (Ed.), “The structure, reacations, synthesis, and uses of heterocyclic compounds,” Comprehensive Heterocyclic Chemistry II, A review of Literature 1982-1995, vol. 6, 120-130.
Chalmers, D.T., et al., “Corticotrophin-releasing factor receptors: from molecular biology to drug design,”TiPS, 1996, 17, 166-173.
Chrousos, G.P., “The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes,”Int. J. Obesity, 2000, 24(Suppl. 2), S50-S55.
De Souza, E.B., “CRH defects in alzheimer's and other neurologic diseases,”Hosp. Practice, Sep. 15, 1988, 59-71.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress response?,”Brain Research Reviews, 1990, 15, 71-100.
Funk, D., et al., “Role of catecholamines in the frontal cortex in the modulation of basal and stress-induced autonomic output in rats,”Brain Res., 1996, 741, 220-229.
Gilligan, P.J., et al., “Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents,”J. Medicinal Chem., May 4, 2000, 43(9), 1641-1660.
Griebel, G., et al., “Genetic differences in the mouse defense test battery,”Aggress. Behav., 1997, 23, 19-31.
Grigoriadis, D.E., et al., “Corticotropin-releasing factor (CRF) receptors in intermediate lobe of the pituitary: biochemical characterization and autoradiographic localization,”Peptides, 1989, 10, 179-188.
Heinrichs, S.C., et al., “Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervouse system disorders,”Ballier's Clinical Endocrinology and Metabolism, 1999, 13(4), 541-554.
Hoffman, J.M., “Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors,”J. Med. Chem., 1993, 36, 953-966.
Huynh, C., et al., “Copper-catalysed reactions of grignard reagents with epoxides and oxetane,”Tetrahedron Letters, 1979, 17, 1503-1506.
Koob, G.F., et al., “Neurobiology of addition toward the development of new therapies,”Ann. N.Y. Acad. Sci., 2000, 909, 170-185.
Maillot, C., et al., “Peripheral corticotrophin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats,”Gastroenterology, 2000, 119, 1569-1579.
Mastorakos, G., et al., “Maternal hypothalamic-pituitary-adrenal axis in pregnancy and the postpartum period,”Ann. N.Y. Acad. Sci., 2000, 900, 95-106.
McCarthy, J. R., et al., “Recent advances with the CRF1receptor: design of small molecule inhibitors, receptor subtypes and clinical indications,”Current Pharmaceutical Design, 1999, 5, 289-315.
Misslin, R., et al., “Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents,”Behav. Process, 1989, 18, 119-132.
Negishi, E., et al., “Selective carbon-carbon bond formation via transition metal catalysis.3. A highly selective synthesis of unsymmetrical biaryls and diarylmethanes by the nickel-or-palladium-catalyzed reaction of aryl-and benzylzinc derivatives with aryl halides,”J. Org. Chem., 1977, 42(10), 1821-1823.
Newport, D.J., et al., “Neurobiology of posttraumatic stress disorder,”Curr. Opin. In Neurobiology, 2000, 10, 211-218.
Owens, M.J., et al., “Corticotropin-releasing factor antagonists in affective disorders,”Exp. Opin. Invest. Drugs, 1999, 8(11), 1849-1858.
Pellow, S., et al., “Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat,”J. Neurosci. Methods, 1985, 14, 149-167.
Porsolt, D.R., et al., “Depression: a new animal model sensitive to antidepressant treatments,”Nature, Apr. 21, 1997, 266, 730-732.
Sato, M., et al., “Cross-coupling reaction of alkyl- or arylboronic acid esters with organic halides induced by thallium(I) salts and palladium-catalyst,”Chem. Letters, 1989, 1405-1408.
Speicher, A., et al., “Syntheses of chlorinated bisbibenzyls from bryophytes,”Synthesis, 2002, 17, 2503-2512.
Tomczuk, B.E., et al., “2-pheyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics,”J. med. Chem., 1991, 34, 2993-3006.
Vogel, J.R., et al., “A simple and reliable conflict procedure for testing anti-anxiety agents,”Psychopharmcologia(Berl.), 1971, 21, 1-7.
Webster, E.L., et al., “Corticotropin-releasing hormone and inflammation,”Ann. N.Y. Acad. Sci., 1998, 840, 21.
Willner, P., et al., “An animal model of anhedonia,”Clin. Neuropharmacol., 1992, 15(Supple. 1), 550A-551A.
Wynn, P.C., et al., “Regulation of corticotrophin-releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF receptors and corticotroph responses,”The Endocrinology Soc., 1985, 116(4), 1653-1659.
Copy of the PCT International Search Report dated Feb. 11, 2004 (PCT/US03/30570).
Arvanitis Argyrios George
Dzierba Carolyn Diane
Sielecki-Dzurdz Thais Motria
Bristol--Myers Squibb Company
Makujina Shah R.
McKenzie Thomas C.
Woodcock & Washburn LLP
LandOfFree
Pyridino and pyrimidino pyrazinones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridino and pyrimidino pyrazinones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridino and pyrimidino pyrazinones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3658424